Shares of Novavax Inc. NVAX, -6.03% gained 0.9% in premarket trading on Thursday after the company said its COVID-19 vaccine received conditional authorization in the U.K. The protein-based vaccine, which is called Nuvaxovid, requires two shots spaced 21 days apart and can be used in adults. The U.K. has already ordered up to 60 million doses of Novavax’s vaccine. The company announced that it filed for authorization in the U.S. on Monday. Novavax’s stock has tumbled 68.5% over the past year, while the S&P 500 SPX, +0.94% has gained 19.9%.
This article was originally published by Marketwatch.com. Read the original article here.
